Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients |
| |
| Authors: | Bernd Schmidt Julia Beyer Dimo Dietrich Ines Bork Volker Liebenberg Michael Fleischhacker |
| |
| Affiliation: | 1Clinic for Internal Medicine I, Department of Pneumology, UKH, Halle/Saale, Germany;2University Hospital Bonn, Institute of Pathology, Bonn, Germany;3Metanomics Health GmbH, Berlin, Germany;H. Lee Moffitt Cancer Center & Research Institute, UNITED STATES |
| |
| Abstract: | PurposeMost patients suffering from advanced lung cancer die within a few months. To exploit new therapy regimens we need better methods for the assessment of a therapy response.ResultsAccording to the re-staging of 31 first-line patients, 19 patients were classified as non-responders while 12 patients were in the responder group. We observed a tight correlation between radiological data and the change of plasma mSHOX2 level as the equivalent for a therapy response. A ROC analysis showed a high discriminatory power for both patient groups already one week after therapy start (AUC 0.844). Additionally, a Kaplan-Meier and Cox Proportional Hazards analyses revealed a strong relationship between survival and plasma mSHOX2 value p≤0.001 (hazard ratio 11.08) providing some evidence for mSHOX2 also being a predictive marker.ConclusionThe longitudinal measurement of extracellular plasma mSHOX2 DNA yields information about the response to cytotoxic treatment and allows an early assessment of treatment response for lung cancer patients. If confirmed in a larger study this would be a valuable tool for selecting and guiding a cytotoxic treatment. |
| |
| Keywords: | |
|
|
